Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM -0.17%89 3-Year EBITDA Growth Rate is 9.40% as of Jun. 2026, which is 32% below its 10-year median of 13.90. GuruFocus rates LTS:0JDM with a GF Score™ of 89/100 and a GF Value™ of $245.75 (Fairly Valued). The stock has 8 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, IQVIA Holdings ranks worse than 51.52% on this metric.
During the past 12 months, IQVIA Holdings's average EBITDA Per Share Growth Rate was 10.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 14.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IQVIA Holdings was 22.20% per year. The lowest was 5.80% per year. And the median was 13.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
IQVIA Holdings 3-Year EBITDA Growth Rate Related Terms
LTS:0JDM vs WAT, NTRA, A: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.40% mean?
IQVIA Holdings (LTS:0JDM) has a 3-Year EBITDA Growth Rate of 9.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IQVIA Holdings and its competitors. This is 32% below median its historical median of 13.90. Over the past decade, IQVIA Holdings' 3-Year EBITDA Growth Rate has ranged from 5.80 to 22.20. According to the industry distribution chart, IQVIA Holdings ranks #85 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 51.5%.
Is IQVIA Holdings' 3-Year EBITDA Growth Rate too high?
IQVIA Holdings' current 3-Year EBITDA Growth Rate of 9.40% is 32% below median its 10-year median of 13.90. Over the past 10 years, this metric has ranged from a low of 5.80 to a high of 22.20. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. IQVIA Holdings' value of 9.40% is 14.5% below this industry median. Based on the distribution chart, IQVIA Holdings ranks #85 out of 165 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' 3-Year EBITDA Growth Rate compare to WAT and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #85 out of 165 companies for 3-Year EBITDA Growth Rate. This places IQVIA Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. IQVIA Holdings' value of 9.40% is 14.5% below this benchmark. Historically, IQVIA Holdings' own 3-Year EBITDA Growth Rate has ranged from 5.80 to 22.20 over the past decade. While the company's 10-year median is 13.90 vs. the industry median of 11.00, IQVIA Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current 3-Year EBITDA Growth Rate of 9.40% is 14.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current 3-Year EBITDA Growth Rate is 9.40%, which is 32% below median its own 10-year median of 13.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $245.75, compared to a current price of $258.36 — trading 5.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.40%, which is 32% below median its 10-year median of 13.90 and 14.5% below the Medical Diagnostics & Research industry median of 11.00. IQVIA Holdings' overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current 3-Year EBITDA Growth Rate is 9.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be overvalued.
The current stock price of $258.36 is trading 5.1% above its estimated GF Value™ of $245.75.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
3-Year EBITDA Growth Rate: 9.40% (32% below median its 10-year median of 13.90)
GF Value™: $245.75 vs. price of $258.36 (5.1% above fair value)
Industry Position: 14.5% below the Medical Diagnostics & Research median (#85 of 165)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
89GF Score
Get the complete analysis for LTS:0JDM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
